Table 2.
Overview endpoints & clinical results: patients with exposed bone/tendon, treatment with HMX.
| Type of study | # of subjects | Type of indication | Primary endpoint, % reached | Secondary Endpoint, % reached |
|---|---|---|---|---|
| Vindigni et al.56 | 1 | Excision squamous cell carcinoma | Full reepithelialization: 100% |
N/A? |
| Caravaggi et al.41 | 23 | Diabetic foot ulcer with exposed bone/tendon | Full reepithelialization: With STSG: 17% 2ND Intention: 26% |
“Rebuilding” dermis: 57% |
| Dessy et al.46 | 10 | Skin carcinoma | Graft take: 97% (80% of subjects: 100%) |
Average patient satisfaction (VAS, 1–10): 8.5 |
| Valenti et al.44 | 15 | Trauma with exposed bone/tendon | Full reepithelialization: 100%: With STSG: 33% 2ND Intention: 67% |
Optimal or good quality of skin: 80% |
| Caravaggi et al.42 | 262, 95 exposed tendon or bone | Ulcers of different etiology | Reepithelialization ≥ 10% from wound edges: 83% (16 days) | Reduction of pain: nearly 3-fold within 30 days of primary application. |